Drug Trial Radar · NCT01331837
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Last checked: Nov 20, 2026Latest source record: Jul 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,080
Actual
Start
Aug 2, 2011
Primary completion
Mar 25, 2016
Study completion Mar 25, 2016
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA). Participants will be randomized to receive intravenous (IV) 8 milligrams per kilogram (mg/kg) tocilizumab every 4 weeks or subcutaneous 50 milligrams (mg) etanercept weekly, with or without non-biologic disease-modifying anti-rheumatic drug (DMARD).
Conditions
- Rheumatoid Arthritis
Interventions
EtanerceptDrug
Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
TocilizumabDrug
Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated EventTime frame: From baseline up to 4.9 years
- Percentage of Patients Reporting a Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated EventTime frame: From baseline up to 4.9 years
- Time to First CV-EAC Adjudicated Event - Sensitivity AnalysisTime frame: From Baseline up to 4.9 years
- Percentage of Patients With a CV-EAC Adjudicated Event - Sensitivity AnalysisTime frame: From Baseline up to 4.9 years
- Time to First CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity AnalysisTime frame: From baseline up to 4.9 years
- Percentage of Patients With a CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity AnalysisTime frame: From baseline up to 4.9 years
- Time to First CV-EAC Adjudicated Event Before Last Direct Contact DateTime frame: From Baseline up to 4.9 years
- Percentage of Participants With a CV-EAC Adjudicated Event Before Last Direct Contact DateTime frame: From Baseline up to 4.9 years
Locations
428 sites in 31 countries. Site status is shown where the registry gives one.
Uni Of Alabama,Birmingham; Medicine - Rheumatology
Birmingham, Alabama
Rheumatology Associates of North Alabama
Huntsville, Alabama
Clinical and Translational Research Center of Alabama, PC
Tuscaloosa, Alabama
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona
Arizona Arthritis & Rheumatology Research, Pllc
Paradise Valley, Arizona
Sun Valley Arthritis Center
Peoria, Arizona
Valley Arthritis Care
Phoenix, Arizona
Advanced Arthritis Care & Research
Scottsdale, Arizona
Camp Lowell Medical Specialists
Tucson, Arizona
The University of Arizona
Tucson, Arizona
NEA Baptist Clinic
Jonesboro, Arkansas
OrthoArkansas; Orthopedics & Sports Medicine
Little Rock, Arkansas
Samy Metyas, MD, Inc
Covina, California
Talbert Medical Group
Huntington Beach, California
Allergy & Rheumatology Medical Clinic, Inc
La Jolla, California
Valerius Medical Group
Los Alamitos, California
Clinical Interventions Research Institute
Mission Viejo, California
Dr. Brigid Freyne, MD
Murrieta, California
Sharp Rees-Stealy Medical Group
Poway, California
San Diego Arthritis Med Clnc
San Diego, California
Purushotham & Akther Kotha Inc
San Diego, California
C Michael Neuwelt MD Inc
San Leandro, California
Pacific Arthritis Ctr Med Grp
Santa Maria, California
Orrin M. Troum, Md
Santa Monica, California
Harbor UCLA Medical Center
Torrance, California
Inland Rheumatology; Clinical Trials, Inc.
Upland, California
Medvin Clinical Research
Whittier, California
Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
Colorado Springs, Colorado
Joao Nascimento
Bridgeport, Connecticut
University of Connecticut Health Center
Farmington, Connecticut
Arthritis & Osteoporosis Center Pc
Hamden, Connecticut
ZASA Clinical Research
Boynton Beach, Florida
DC Health Clinic
Coral Gables, Florida
Tsai, Yong
Daytona Beach, Florida
Jacksonville Center For Clinical Research
Jacksonville, Florida
Pharmax Research Clinic Inc.
Miami, Florida
Arthritis/Osteoporosis Treatment Center
Orange Park, Florida
Arthritis Rsrch of Florida, Inc.
Palm Harbor, Florida
Baptist Hospital Clinical Research
Pensacola, Florida
Lovelace Scientific Resources
Sarasota, Florida
Showing 40 of 428 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.